merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Because Lilly can offer a lower-priced, FDA-approved and oversight-controlled (safer) alternative to compounded drugs.</answer>
<question_number>2</question_number>
<answer>By selling FDA-made vials directly through LillyDirect, bypassing third-party supply chains and delivering to patients, directly competing with telehealth firms that route customers to compounded medications.</answer>
<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight, raising safety, quality and effectiveness concerns.</answer>
<question_number>4</question_number>
<answer>To undercut compounded competitors and win back customers by offering cheaper vials even if some pen buyers switch to the lower-priced vials.</answer>
<question_number>5</question_number>
<answer>Being on the FDA shortage list lets compounders legally make alternatives; removing tirzepatide from the list would eliminate space for mass compounding and aid Lilly's legal efforts.</answer>
<question_number>6</question_number>
<answer>It illustrates pharma bypassing intermediaries to sell direct to consumers with "transparent pricing," removing third-party supply chains to offer lower prices.</answer>
<question_number>7</question_number>
<answer>Medicare beneficiaries may pay out-of-pocket for the vials despite lack of coverage, potentially exposing older patients to added risks like muscle loss and fractures.</answer>
<question_number>8</question_number>
<answer>It may lead patients to view compounded tirzepatide as less safe and unregulated, encouraging them to switch to Lilly's FDA-produced vials.</answer>
<question_number>9</question_number>
<answer>It is listed as "in shortage" by the FDA.</answer>
<question_number>10</question_number>
<answer>Using lower pricing (offering cheaper vials) as a signal to undercut and regain market share from compounding pharmacies.</answer>